The Effect of Complement Factor H Y402H Polymorphism on the Outcome of Photodynamic Therapy in Age-related Macular Degeneration

Abstract

The dysfunction of the CFH related to the risk of AMD and caused by the Y402H polymorphism does not modify the outcome of PDT. Genotyping for CFH Y402H cannot be used to select patients for this treatment.

Positive Association of Complement Factor H Gene Variants with the Effect of Photodynamic Therapy in Polypoidal Choroidal Vasculopathy

“…Previous reports evaluated only CFH Y402H as a predictor for the outcome of PDT in neovascular AMD [10][11][12][13][14]. However, our results suggested that the association for the response to PDT was not only with Y402H, but also with rs1410996 in the CFH region.…”

“…Although the conclusions of previous reports regarding the association of CFH with the effects of PDT in neovascular AMD were contradictory [10][11][12][13][14], we found that coding variants in CFH were significantly associated with the response to PDT in PCV. This may be explained by differences in the phenotype (neovascular AMD vs PCV) or differences in the method of subgroup classification.…”

“…This may be explained by differences in the phenotype (neovascular AMD vs PCV) or differences in the method of subgroup classification. Unlike many previous studies [10][11][12][13][14], we classified PDT responders and nonresponders based on objective findings including fundus photography, FA and OCT. The classifications between "PDT-responder" and "nonresponder" according with objective (anatomical) findings are also seen in recent publications [25,26].…”

“…Recently, genetic variants in the complement factor H (CFH) gene on chromosome 1q32 have been tested to explain the response to PDT [10][11][12][13][14]. In particular, the Y402H coding variant (rs1061170) in CFH is presumed to have functional consequences consistent with AMD pathology [15][16][17][18][19] and most studies have been conducted to find that CFH Y402H correlates with the outcome of PDT [10][11][12][13][14]. In neovascular AMD, Brantley et al [12] reported an association of the CFH Y402H variant with the visual outcome after PDT [12].…”

Importance of genetic polymorphisms in the response to age-related macular degeneration treatment

“…(62) Other studies did not show significant association between CFH polymorphism and PDT response for neovascular AMD. (63,64) For LOC387715, two important studies have shown that there is no statistical significant difference among the genotypes in response to PDT. (62,65) However, Sakurada et al have recently shown that there is a pharmacogenetic association between the LOC387715 A69S variant and the long-term results after PDT in eyes with polypoidal choroidal vasculopathy (PCV).…”